Upper gastrointestinal (UGI) tolerability of valdecoxib, A Cox-2 specific inhibitor, compared with nonspecific (NS) NSAIDs among patients with osteoarthritis (OA) and rheumatoid arthritis (RA)

被引：1

|

作者：

Goldstein, JL

Eisen, GM

Hanna, DB

Burke, T

机构：

来源：

GASTROENTEROLOGY | 2003年 / 124卷 / 04期

关键词：

D O I：

10.1016/S0016-5085(03)82590-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：A511 / A512

页数：2

相关论文

共 37 条

[1] Upper gastrointestinal (UGI) tolerability of valdecoxib, a COX-2 specific inhibitor, compared with nonspecific NSAIDs among patients with osteoarthritis and rheumatoid arthritis
Goldstein, JL
Eisen, G
Hanna, DB
Burke, T
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 278 - 279
[2] Valdecoxib provides similar efficacy and improved upper GI safety compared with nonspecific NSAIDs in elderly patients with osteoarthritis (OA) or rheumatoid arthritis (RA).
Kivitz, A
Bensen, W
Makarowski, W
Riley, W
Bevirt, T
Verburg, KM
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (04) : S99 - S99
[3] Valdecoxib, a novel COX-2 specific inhibitor, is safe and well tolerated in elderly osteoarthritis (OA) and rheumatoid arthritis (RA) patients.
Recker, DP
Kent, JD
Hounslow, N
Lau, W
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (04) : S144 - S145
[4] Upper gastrointestinal (UGI) tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen, WG
Agrawal, NM
Zhao, SZ
Burke, TA
Zabinski, RA
Maurath, CJ
Hamilton, GSG
ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S142 - S142
[5] Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis
Eisen, GM
Goldstein, JL
Hanna, DB
Rublee, DA
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (05) : 591 - 598
[6] Valdecoxib is less ulcerogenic than nonspecific NSAIDs in osteoarthritis (OA) and rheumatoid arthritis (RA) patients with high risk of peptic ulcer disease
Goldstein, JL
Kent, J
Shu, V
Maurath, C
Recker, D
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 414 - 414
[7] Valdecoxib - A COX-2 inhibitor for treatment of osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea
Goldman, M
Schutzer, S
FORMULARY, 2002, 37 (02) : 68 - +
[8] Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo
Bensen, WG
Zhao, SZ
Burke, TA
Zabinski, RA
Makuch, RW
Maurath, CJ
Agrawal, NM
Geis, GS
JOURNAL OF RHEUMATOLOGY, 2000, 27 (08) : 1876 - 1883
[9] Celecoxib, a COX-2 specific inhibitor, is associated with a lower incidence of serious upper gastrointestinal (UGI) events in arthritis patients than comparator NSAIDs.
Goldstein, JL
Agrawal, NM
Silverstein, F
Hubbard, RC
Zhao, W
Geis, GS
ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S280 - S280
[10] Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis
Rabeneck, L
Goldstein, JL
Vu, A
Mayne, TJ
Rublee, DA
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (05): : 1043 - 1050

← 1 2 3 4 →